Oxford Biomedica Welcomes Leone Patterson as New Non-Executive Director

Oxford BioMedica PLC (LSE:OXB) is delighted to announce the appointment of Ms. Leone Patterson as an Independent Non-Executive Director, who will join the Board on 1st May 2023. With her wealth of experience, Ms Patterson will bring quality and innovation to the Company’s viral vector CDMO.

Ms Patterson boasts an impressive 20+ year career in the biotech industry. She has overseen immense growth within international commercial companies, applying her expertise in strategy, finance, operations, and governance. Her impressive experience also spans across the cell and gene therapy sector.

Ms. Patterson is a highly experienced executive with a wealth of knowledge in finance and business. She is currently the Chief Financial and Business Officer at Tenaya Therapeutics, a clinical-stage company with a mission to discover, develop, and deliver potentially curative therapies, including gene therapy, for heart disease.

Additionally, she serves on the Board of Directors for Nkarta, a clinical-stage cell therapy company. Ms. Patterson has held leadership roles at Adverum Biotechnologies, a gene therapy company focused on rare and ocular diseases, where she was the Chief Executive Officer and Chief Financial Officer.

Additionally, she has previously held the role of Chief Financial Officer at public companies, such as diagnostics firm Diadexus, speciality pharmaceuticals provider Transcept Pharmaceuticals, and Novartis, Chiron and KPMG. Ms. Patterson has a B.S. in business administration and accounting from Chapman University, an executive M.B.A. from St. Mary’s College, and is a Certified Public Accountant (inactive).

Dr. Roch Doliveux, Chair of Oxford Biomedica, is delighted to welcome Leone as the newest addition to the team. Her unparalleled experience in corporate finance, US public markets and M&A, as well as her extensive knowledge of the cell and gene therapy industry, will be crucial in furthering Oxford Biomedica’s international strategy and solidifying its market position.

This appointment arrives at an opportune moment as the company works to become the global leader in viral vector development and supply, providing innovative solutions to biopharma customers around the world.

I am thrilled to join the Board of Oxford Biomedica, a world-leading CDMO dedicated to driving the development of life-saving cell and gene therapies. I am eager to collaborate with the Board and leverage my expertise to help propel the Company to further success.

In June 2016, Diadexus, with Ms. Patterson as its Chief Financial Officer, made the difficult decision to file for Chapter 7 bankruptcy. No further disclosure was necessary in accordance with LR 9.6.13R.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a forward-thinking, innovative CDMO focused on advancing viral vector therapies to treat life-altering conditions. Our mission is to empower our clients to make a difference in the lives of those who need help most. By combining quality and creativity, we are dedicated to bringing breakthrough treatments to people around the world.

For over 25 years, Oxford Biomedica has been a trailblazer in the field of cell and gene therapy, relying on the power of viral vectors to bring some of the world’s most innovative treatments to life.

With expertise in lentivirus, adeno-associated virus (AAV), and adenoviral vectors, the company offers a comprehensive suite of services, from early-stage development to commercialisation.

Backed by robust quality assurance systems, reliable analytical methods, and extensive regulatory knowledge, Oxford Biomedica is uniquely positioned to make a lasting impact on the future of healthcare.

Oxford Biomedica, a FTSE4Good constituent, is an innovative biotechnology company headquartered in Oxford, UK. With locations across Oxfordshire and a US-based subsidiary, Oxford Biomedica Solutions, near Boston, MA, the company is leading the way in developing cutting-edge treatments and therapies for a range of diseases.

Leave a Comment